Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma
Trial Sites
Back to Top
Basic Trial Information
Trial Description
Summary
Further Trial Information
Eligibility Criteria
Trial Contact Information
| Phase | Type | Status | Age | Sponsor | Protocol IDs |
|---|---|---|---|---|---|
| Phase II | Biomarker/Laboratory analysis, Supportive care, Treatment | Active | 60 and over | NCI, Other | CDR0000707057 ECOG-E1411, E1411, NCT01415752 |
Summary
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some find cancer cells and help kill them or carry cancer-killing substances to them. Others interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as bendamustine hydrochloride, also work in different ways to kill cancer cells or stop them from dividing. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Lenalidomide may stop the growth of mantle cell lymphoma by blocking blood flow to the cancer. It is not yet known whether giving rituximab together with bendamustine and bortezomib is more effective than rituximab and bendamustine, followed by rituximab alone or with lenalidomide in treating mantle cell lymphoma.
PURPOSE: This randomized phase II trial studies rituximab, bortezomib, bendamustine, and lenalidomide in treating previously untreated older patients with mantle cell lymphoma.
Further Study Information
OBJECTIVES:
Primary
- To determine whether the addition of bortezomib (RBV) to an induction regimen of rituximab-bendamustine hydrochloride (RB) improves progression-free survival (PFS) compared to RB alone in patients ≥ 60 years of age with previously untreated mantle cell lymphoma.
- To determine whether the addition of lenalidomide to a consolidation regimen of rituximab following an induction regimen of RB or RBV improves PFS compared to consolidation rituximab alone in this patient population.
Secondary
- To determine whether the addition of bortezomib to induction therapy improves the positron emission tomography (PET)-documented complete response (CR) rate compared to RB alone.
- To determine the objective response rate (ORR) for RB and RBV.
- Among patients who do not have PET-documented CR at the end of induction, to determine whether the addition of lenalidomide to consolidation therapy improves CR and ORR compared with rituximab alone.
- To determine overall survival (OS) in the treatment arms.
- To determine safety, with attention to the addition of bortezomib in the induction regimen and lenalidomide-rituximab (LR) as consolidation therapy.
- To collect paraffin-embedded tissue for creation of tissue microarray.
- To collect and bank serum and blood mononuclear cells for future studies.
- To collect formalin-fixed paraffin-embedded (FFPE) tissue to analyze potential prognostic factors (Ki-67 proliferation index by immunohistochemistry and correlation with proposed 5-gene set of proliferation markers analyzed by RNA PCR; SOX 11 expression by immunohistochemistry; and Micro-RNA levels by microarray).
- Using patient-reported outcomes data, to determine the extent and severity of neuropathy associated with the addition of bortezomib to induction treatment.
- Using patient-reported outcomes data, to determine the extent and severity of fatigue associated with the addition of lenalidomide to consolidation treatment.
- To evaluate the effects of the addition of bortezomib and lenalidomide on patient-reported health-related quality of life.
- To evaluate the effects of bortezomib-related neuropathy on patient-reported health-related quality of life.
- To evaluate the response of lymphoma-specific symptoms to treatment.
- Using longitudinal patient-reported outcomes data, to describe the trajectory of lymphoma symptoms, neuropathy, fatigue, and overall health-related quality of life prior to, during, and following treatment among older adults with MCL.
Tertiary
- To assess the proportion of patients up and down staging when fludeoxyglucose F 18- (FDG) PET/CT is added to standard Ann Arbor staging.
- To assess the ability of pre-treatment FDG-PET/CT (SUVmax) to predict response rate and PFS.
- Among patients with interim (post-cycle 3) FDG-PET/CT imaging, to assess the correlation of interim FDG-PET/CT imaging with response rate and PFS both during induction and consolidation therapy.
- To assess standard FDG-PET/CT metrics including SUVmax, tumor metabolic burden, total tumor burden, and association with pathology features (blastoid variant vs other, and Ki67) in the setting of MCL.
- To assess differences in overall and CR rates when using Deauville vs International Harmonization Project FDG-PET/CT interpretation criteria.
- To determine whether there is a correlation between FDG-PET/CT response and residual disease assessment by molecular and/or flow cytometric techniques.
- To determine whether the number of malignant cells in circulation predict the number of cells in marrow.
- To determine whether the number of malignant cells in circulation/in marrow at the end of induction correlate with CR and 2-year PFS.
- To determine whether there is a higher rate of minimal residual disease (MRD) negativity among patients randomized to RBV as compared with RB, and among patients treated with LR maintenance compared with rituximab.
- To compare the two methods of MRD detection - molecular techniques and flow cytometry - as prognostic markers for outcome.
OUTLINE: This is a multicenter study. Patients are stratified according to mantle cell lymphoma International Prognostic Index risk score (low vs intermediate vs high). Patients are randomized to 1 of 4 treatment arms.
- Arm A: Patients receive induction therapy comprising rituximab IV on day 1 and bendamustine hydrochloride IV over 60 minutes on days 1-2. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.
- Arm E: Patients receive consolidation therapy comprising rituximab IV on day 1. Courses repeat every 8 weeks for 2 years in the absence of disease progression or unacceptable toxicity.
- Arm B: Patients receive induction therapy comprising bortezomib IV or subcutaneously (SC) on days 1, 4, 8, and 11 and rituximab and bendamustine hydrochloride as patients in arm A. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.
- Arm F: Patients receive consolidation therapy comprising rituximab IV on day 1. Courses repeat every 8 weeks for 2 years in the absence of disease progression or unacceptable toxicity.
- Arm C: Patients receive induction therapy comprising rituximab and bendamustine hydrochloride as patients in arm A. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.
- Arm G: Patients receive consolidation therapy comprising lenalidomide orally (PO) daily on days 1-21 every 4 weeks and rituximab IV every 8 weeks for 2 years in the absence of disease progression or unacceptable toxicity.
- Arm D: Patients receive bortezomib, rituximab, and bendamustine hydrochloride as patients in arm B. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.
- Arm H: Patients receive consolidation therapy comprising lenalidomide PO daily on days 1-21 every 4 weeks and rituximab IV every 8 weeks for 2 years in the absence of disease progression or unacceptable toxicity.
Patients may undergo blood and bone marrow sample collection at baseline and during treatment for correlative studies.
Patients complete the Functional Assessment of Cancer Therapy - Lymphoma (FACT-Lym), the FACT/GOG-Neurotoxicity scale (FACT/GOG-Ntx), FACT-Fatigue, and FACT-General questionnaires at baseline and periodically during study and follow up.
After completion of study treatment, patients are followed up every 3 months for 2 years, every 6 months for 3 years, and then annually for 10 years.
Eligibility Criteria
DISEASE CHARACTERISTICS:
- Histologically confirmed untreated mantle cell lymphoma (MCL), with documented cyclin D1 by immunohistochemical stains and/or t(11;14) by cytogenetics or fluorescence in situ hybridization (FISH)
- Patients must have at least one objective measurable disease parameter
- Abnormal PET scans will not constitute evaluable disease, unless verified by CT scan or other appropriate imaging
- Measurable disease in the liver is required if the liver is the only site of lymphoma
- Patient must have no CNS involvement
PATIENT CHARACTERISTICS:
- ECOG performance status 0-2
- ANC ≥ 1,500/mcL (1.5 x 10^9/L)*
- Platelets ≥ 100,000/mcL (100 x 10^9/L)* NOTE: *Unless due to marrow involvement.
- AST/ALT ≤ 2 times upper limit of normal (ULN)
- Bilirubin ≤ 2 times ULN
- Calculated creatinine clearance by Cockroft-Gault formula ≥ 30 mL/min
- Women (sexually mature female) must not be pregnant or breast-feeding
- Negative pregnancy test
- Women of childbearing potential and sexually active males use an accepted and effective method of contraception
- Men must agree to use a latex condom during sexual contact with a female of child-bearing potential, even if they have had a successful vasectomy
- All patients must be counseled at a minimum of every 28 days about pregnancy precautions and risks of fetal exposure
- No evidence of prior malignancy except adequately treated non-melanoma skin cancer, in situ cervical carcinoma, or any surgically or radiation-cured malignancy continuously disease free for ≥ 5 years so as not to interfere with interpretation of radiographic response
- Patient agrees that if randomized to Arms C or D, and proceed onto Arms G or H, they must register into the mandatory RevAssist® program, and be willing and able to comply with the requirements of RevAssist®
- Patients must have no medical contra-indications to, and be willing to take, deep vein thrombosis (DVT) prophylaxis as all patients registering to the lenalidomide/rituximab Arms G and H will be required to have DVT prophylaxis
- Patients randomized to Arms G or H who have a history of a thrombotic vascular event will be required to have therapeutic doses of low-molecular weight heparin or warfarin to maintain an INR between 2.0 - 3.0
- Patients on Arms G and H without a history of a thromboembolic event are required to take a daily aspirin (81 mg or 325 mg) for DVT prophylaxis
- Patients who are unable to tolerate aspirin should receive low molecular weight heparin therapy or warfarin treatment
- Women must agree to abstain from donating blood during study participation and for at least 28 days after discontinuation from protocol treatment
- Males must agree to abstain from donating blood, semen, or sperm during study participation and for at least 28 days after discontinuation from protocol treatment
- HIV-positive patients are not excluded but, to enroll, must meet all of the below criteria:
- HIV is sensitive to antiretroviral therapy
- Must be willing to take effective antiretroviral therapy, if indicated
- No history of CD4 prior to or at the time of lymphoma diagnosis < 300 cells/mm³
- No history of AIDS-defining conditions
- If on antiretroviral therapy, must not be taking zidovudine or stavudine
- Must be willing to take prophylaxis for Pneumocystis jiroveci pneumonia (PCP) during therapy and until at least 2 months following the completion of therapy or until the CD4 cells recover to over 250 cells/mm³, whichever occurs later
- Patients must not have grade 2 or greater peripheral neuropathy
- Patients must not have NYHA Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia
- Patients must not have hypersensitivity to bortezomib, boron, or mannitol
- Patients must not have a serious medical or psychiatric illness likely to interfere with study participation
PRIOR CONCURRENT THERAPY:
- No prior therapy for MCL, except < 1 week of steroid therapy for symptom control
- HIV-positive patients are not excluded, but to enroll, must meet all of the below criteria:
- Must be willing to take effective antiretroviral therapy if indicated
- If on antiretroviral therapy, must not be taking zidovudine or stavudine
- Patients must not be participating in any other clinical trial or taking any other experimental medications within 14 days prior to registration
Trial Lead Organizations/Sponsors
Eastern Cooperative Oncology Group
National Cancer Institute| Mitchell Reed Smith |  | Principal Investigator |
Trial Sites
|
|
|
|
| U.S.A. | |||
|
|||
| California | |||
|
|||
| Antioch | |||
|
|||
| Kaiser Permanente - Deer Valley | |||
| Tatjana Kolevska | Ph: 626-564-3455 | ||
| Fremont | |||
|
|||
| Kaiser Permanente - Fremont | |||
| Tatjana Kolevska | Ph: 626-564-3455 | ||
| Fresno | |||
|
|||
| Kaiser Permanente Fresno Medical Center | |||
| Tatjana Kolevska | Ph: 626-564-3455 | ||
| Hayward | |||
|
|||
| Kaiser Permanente Medical Center - Hayward | |||
| Tatjana Kolevska | Ph: 626-564-3455 | ||
| Modesto | |||
|
|||
| Kaiser Permanente-Modesto | |||
| Tatjana Kolevska | Ph: 626-564-3455 | ||
| Oakland | |||
|
|||
| Kaiser Permanente-Oakland | |||
| Tatjana Kolevska | Ph: 626-564-3455 | ||
| Redwood City | |||
|
|||
| Kaiser Permanente Medical Center - Redwood City | |||
| Tatjana Kolevska | Ph: 626-564-3455 | ||
| Richmond | |||
|
|||
| Kaiser Permanente Medical Center - Richmond | |||
| Tatjana Kolevska | Ph: 626-564-3455 | ||
| Roseville | |||
|
|||
| Kaiser Permanente Medical Center - Roseville | |||
| Tatjana Kolevska | Ph: 626-564-3455 | ||
| Sacramento | |||
|
|||
| Kaiser Permanente Medical Center - Sacramento | |||
| Tatjana Kolevska | Ph: 626-564-3455 | ||
| South Sacramento Kaiser-Permanente Medical Center | |||
| Tatjana Kolevska | Ph: 626-564-3455 | ||
| San Francisco | |||
|
|||
| Kaiser Permanente Medical Center - San Francisco Geary Campus | |||
| Tatjana Kolevska | Ph: 626-564-3455 | ||
| San Jose | |||
|
|||
| Kaiser Permanente Medical Center - Santa Teresa | |||
| Tatjana Kolevska | Ph: 626-564-3455 | ||
| San Rafael | |||
|
|||
| Kaiser Foundation Hospital - San Rafael | |||
| Tatjana Kolevska | Ph: 626-564-3455 | ||
| Santa Clara | |||
|
|||
| Kaiser Permanente Medical Center - Santa Clara Homestead Campus | |||
| Tatjana Kolevska | Ph: 626-564-3455 | ||
| Santa Rosa | |||
|
|||
| Kaiser Permanente Medical Center - Santa Rosa | |||
| Tatjana Kolevska | Ph: 626-564-3455 | ||
| South San Francisco | |||
|
|||
| Kaiser Permanente Medical Center - South San Francisco | |||
| Tatjana Kolevska | Ph: 626-564-3455 | ||
| Stanford | |||
|
|||
| Stanford Cancer Center | |||
| Ranjana Advani | Ph: 650-498-7061 | ||
| Email: clinicaltrials@med.stanford.edu | |||
| Stockton | |||
|
|||
| Kaiser Permanente Medical Facility - Stockton | |||
| Tatjana Kolevska | Ph: 626-564-3455 | ||
| Vacaville | |||
|
|||
| Kaiser Permanente Medical Center - Vacaville | |||
| Tatjana Kolevska | Ph: 626-564-3455 | ||
| Vallejo | |||
|
|||
| Kaiser Permanente Medical Center - Vallejo | |||
| Tatjana Kolevska | Ph: 626-564-3455 | ||
| Walnut Creek | |||
|
|||
| Kaiser Permanente Medical Center - Walnut Creek | |||
| Tatjana Kolevska | Ph: 626-564-3455 | ||
| Colorado | |||
|
|||
| Aurora | |||
|
|||
| Medical Center of Aurora - South Campus | |||
| Eduardo R. Pajon | Ph: 888-785-6789 | ||
| Boulder | |||
|
|||
| Boulder Community Hospital | |||
| Eduardo R. Pajon | Ph: 888-785-6789 | ||
| Colorado Springs | |||
|
|||
| Penrose Cancer Center at Penrose Hospital | |||
| Eduardo R. Pajon | Ph: 888-785-6789 | ||
| Denver | |||
|
|||
| CCOP - Colorado Cancer Research Program | |||
| Eduardo R. Pajon | Ph: 888-785-6789 | ||
| Kaiser Permanente of Colorado | |||
| Alexander Menter | Ph: 303-614-1300 | ||
| Porter Adventist Hospital | |||
| Eduardo R. Pajon | Ph: 888-785-6789 | ||
| Presbyterian - St. Luke's Medical Center | |||
| Eduardo R. Pajon | Ph: 888-785-6789 | ||
| Rose Medical Center | |||
| Eduardo R. Pajon | Ph: 888-785-6789 | ||
| St. Anthony Central Hospital | |||
| Eduardo R. Pajon | Ph: 888-785-6789 | ||
| St. Joseph Hospital | |||
| Eduardo R. Pajon | Ph: 888-785-6789 | ||
| Englewood | |||
|
|||
| Swedish Medical Center | |||
| Eduardo R. Pajon | Ph: 888-785-6789 | ||
| Greeley | |||
|
|||
| North Colorado Medical Center | |||
| Eduardo R. Pajon | Ph: 888-785-6789 | ||
| Lafayette | |||
|
|||
| Kaiser Permanente - Lafayette | |||
| Alexander Menter | Ph: 303-614-1300 | ||
| Littleton | |||
|
|||
| Littleton Adventist Hospital | |||
| Eduardo R. Pajon | Ph: 888-785-6789 | ||
| Lone Tree | |||
|
|||
| Sky Ridge Medical Center | |||
| Eduardo R. Pajon | Ph: 888-785-6789 | ||
| Longmont | |||
|
|||
| Hope Cancer Care Center at Longmont United Hospital | |||
| Eduardo R. Pajon | Ph: 888-785-6789 | ||
| Loveland | |||
|
|||
| McKee Medical Center | |||
| Eduardo R. Pajon | Ph: 888-785-6789 | ||
| Parker | |||
|
|||
| Parker Adventist Hospital | |||
| Eduardo R. Pajon | Ph: 888-785-6789 | ||
| Pueblo | |||
|
|||
| St. Mary - Corwin Regional Medical Center | |||
| Eduardo R. Pajon | Ph: 888-785-6789 | ||
| Wheat Ridge | |||
|
|||
| Exempla Lutheran Medical Center | |||
| Eduardo R. Pajon | Ph: 888-785-6789 | ||
| Connecticut | |||
|
|||
| Hartford | |||
|
|||
| Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center | |||
| Philip J. Stella | Ph: 734-712-3456 | ||
| Delaware | |||
|
|||
| Lewes | |||
|
|||
| Tunnell Cancer Center at Beebe Medical Center | |||
| Gregory A. Masters | Ph: 302-733-6227 | ||
| Newark | |||
|
|||
| Helen F. Graham Cancer Center at Christiana Hospital | |||
| Gregory A. Masters | Ph: 302-733-6227 | ||
| District of Columbia | |||
|
|||
| Washington | |||
|
|||
| Lombardi Comprehensive Cancer Center at Georgetown University Medical Center | |||
| Bruce David Cheson | Ph: 202-444-0381 | ||
| Florida | |||
|
|||
| Jacksonville | |||
|
|||
| Baptist Cancer Institute - Jacksonville | |||
| Troy Hancil Guthrie | Ph: 904-202-7051 | ||
| Orlando | |||
|
|||
| M.D. Anderson Cancer Center at Orlando | |||
| Jose E. Sarriera | Ph: 321-841-7246 | ||
| Hawaii | |||
|
|||
| Aiea | |||
|
|||
| Kapiolani Medical Center at Pali Momi | |||
| Jeffrey L. Berenberg | Ph: 808-586-2979 | ||
| Jeffrey L. Berenberg | Ph: 808-586-2979 | ||
| Honolulu | |||
|
|||
| Cancer Research Center of Hawaii | |||
| Jeffrey L. Berenberg | Ph: 808-586-2979 | ||
| Kaiser Permanente - Moanalua Medical Center and Clinic | |||
| Tatjana Kolevska | Ph: 626-564-3455 | ||
| Kapiolani Medical Center for Women and Children | |||
| Jeffrey L. Berenberg | Ph: 808-586-2979 | ||
| OnCare Hawaii, Incorporated - Kuakini | |||
| Jeffrey L. Berenberg | Ph: 808-586-2979 | ||
| Jeffrey L. Berenberg | Ph: 808-586-2979 | ||
| OnCare Hawaii, Incorporated - Lusitana | |||
| Jeffrey L. Berenberg | Ph: 808-586-2979 | ||
| Queen's Cancer Institute at Queen's Medical Center | |||
| Jeffrey L. Berenberg | Ph: 808-586-2979 | ||
| Straub Clinic and Hospital, Incorporated | |||
| Jeffrey L. Berenberg | Ph: 808-586-2979 | ||
| Kailua | |||
|
|||
| Castle Medical Center | |||
| Jeffrey L. Berenberg | Ph: 808-586-2979 | ||
| Lihue | |||
|
|||
| Kauai Medical Clinic | |||
| Jeffrey L. Berenberg | Ph: 808-586-2979 | ||
| Idaho | |||
|
|||
| Boise | |||
|
|||
| Saint Alphonsus Cancer Care Center at Saint Alphonsus Regional Medical Center | |||
| Philip J. Stella | Ph: 734-712-3456 | ||
| Meridian | |||
|
|||
| Idaho Urologic Institute, PA | |||
| Philip J. Stella | Ph: 734-712-3456 | ||
| Illinois | |||
|
|||
| Chicago | |||
|
|||
| Mount Sinai Hospital Medical Center | |||
| Pam G. Khosla | Ph: 773-257-5960 | ||
| Email: suhi@sinai.org | |||
| Robert H. Lurie Comprehensive Cancer Center at Northwestern University | |||
| Jane N. Winter | Ph: 312-695-1301 | ||
| Email: cancer@northwestern.edu | |||
| Highland Park | |||
|
|||
| Hematology Oncology Associates of Illinois-Highland Park | |||
| Jane N. Winter | Ph: 312-695-1301 | ||
| Email: cancer@northwestern.edu | |||
| Kankakee | |||
|
|||
| Provena St. Mary's Regional Cancer Center - Kankakee | |||
| Jane N. Winter | Ph: 312-695-1301 | ||
| Email: cancer@northwestern.edu | |||
| Libertyville | |||
|
|||
| North Shore Oncology and Hematology Associates, Limited - Libertyville | |||
| Jane N. Winter | Ph: 312-695-1301 | ||
| Email: cancer@northwestern.edu | |||
| Mt. Vernon | |||
|
|||
| Good Samaritan Regional Health Center | |||
| Bethany G. Sleckman | Ph: 913-948-5588 | ||
| Niles | |||
|
|||
| Cancer Care and Hematology Specialists of Chicagoland - Niles | |||
| Jane N. Winter | Ph: 312-695-1301 | ||
| Email: cancer@northwestern.edu | |||
| Rockford | |||
|
|||
| Swedish-American Regional Cancer Center | |||
| Harvey Eric Einhorn | Ph: 815-489-4413 | ||
| Skokie | |||
|
|||
| Hematology Oncology Associates - Skokie | |||
| Jane N. Winter | Ph: 312-695-1301 | ||
| Email: cancer@northwestern.edu | |||
| Indiana | |||
|
|||
| Indianapolis | |||
|
|||
| St. Francis Hospital Cancer Care Services | |||
| Howard M. Gross | Ph: 765-983-3000 | ||
| Lafayette | |||
|
|||
| Clarian Arnett Cancer Care | |||
| Thomas Isaac Jones | Ph: 800-899-8448ext7431 | ||
| Email: sstidham@clarianarnett.com | |||
| Richmond | |||
|
|||
| Reid Hospital & Health Care Services | |||
| Howard M. Gross | Ph: 317-783-8918 | ||
| Iowa | |||
|
|||
| Ames | |||
|
|||
| McFarland Clinic, PC | |||
| Joseph James Merchant | Ph: 515-239-2621 | ||
| Bettendorf | |||
|
|||
| Hematology Oncology Associates of the Quad Cities | |||
| Shobha R. Chitneni | Ph: 563-355-7733 | ||
| Email: kedaprile@rccqc.com | |||
| Cedar Rapids | |||
|
|||
| Cedar Rapids Oncology Associates | |||
| Deborah W Wilbur | Ph: 319-363-2690 | ||
| Deborah W Wilbur | Ph: 319-363-2690 | ||
| Mercy Regional Cancer Center at Mercy Medical Center | |||
| Deborah W Wilbur | Ph: 319-363-2690 | ||
| Sioux City | |||
|
|||
| Mercy Medical Center - Sioux City | |||
| Donald Bruce Wender | Ph: 712-252-0088 | ||
| Siouxland Hematology-Oncology Associates, LLP | |||
| Donald Bruce Wender | Ph: 712-252-0088 | ||
| St. Luke's Regional Medical Center | |||
| Donald Bruce Wender | Ph: 712-252-0088 | ||
| Kansas | |||
|
|||
| Lawrence | |||
|
|||
| Lawrence Memorial Hospital | |||
| Shaker R. Dakhil | Ph: 316-262-4467 | ||
| Wichita | |||
|
|||
| Wesley Medical Center | |||
| Shaker R. Dakhil | Ph: 316-262-4467 | ||
| Louisiana | |||
|
|||
| Baton Rouge | |||
|
|||
| Ochsner Health Center - Bluebonnet | |||
| Robert V. Emmons | Ph: 888-562-4763 | ||
| New Orleans | |||
|
|||
| New Orleans Cancer Institute at Memorial Medical Center | |||
| Robert V. Emmons | Ph: 888-562-4763 | ||
| Ochsner Cancer Institute at Ochsner Clinic Foundation | |||
| Robert V. Emmons | Ph: 888-562-4763 | ||
| Maine | |||
|
|||
| Augusta | |||
|
|||
| Harold Alfond Center for Cancer Care | |||
| Thomas Henry Openshaw | Ph: 207-973-4274 | ||
| Bangor | |||
|
|||
| CancerCare of Maine at Eastern Maine Medical Center | |||
| Thomas Henry Openshaw | Ph: 207-973-4274 | ||
| Maryland | |||
|
|||
| Elkton MD | |||
|
|||
| Union Hospital of Cecil County | |||
| Gregory A. Masters | Ph: 302-733-6227 | ||
| Massachusetts | |||
|
|||
| Worcester | |||
|
|||
| UMASS Memorial Cancer Center - University Campus | |||
| Andrew M Evens | Ph: 508-856-2464 | ||
| Email: laura.lefko@umassmed.edu | |||
| Michigan | |||
|
|||
| Ann Arbor | |||
|
|||
| CCOP - Michigan Cancer Research Consortium | |||
| Philip J. Stella | Ph: 734-712-3456 | ||
| Saint Joseph Mercy Cancer Center | |||
| Philip J. Stella | Ph: 734-712-3456 | ||
| Battle Creek | |||
|
|||
| Battle Creek Health System Cancer Care Center | |||
| Gilbert D Padula | Ph: 616-685-5225 | ||
| Big Rapids | |||
|
|||
| Mecosta County Medical Center | |||
| Gilbert D Padula | Ph: 616-685-5225 | ||
| Dearborn | |||
|
|||
| Oakwood Cancer Center at Oakwood Hospital and Medical Center | |||
| Philip J. Stella | Ph: 734-712-3456 | ||
| Detroit | |||
|
|||
| Van Elslander Cancer Center at St. John Hospital and Medical Center | |||
| Philip J. Stella | Ph: 734-712-3456 | ||
| Wayne State University | |||
| Radhakrishnan Ramchandren | Ph: 313-576-9363 | ||
| Escanaba | |||
|
|||
| Green Bay Oncology, Limited - Escanaba | |||
| Gerald K. Bayer | Ph: 800-432-6049 | ||
| Flint | |||
|
|||
| Genesys Hurley Cancer Institute | |||
| Philip J. Stella | Ph: 734-712-3456 | ||
| Hurley Medical Center | |||
| Philip J. Stella | Ph: 734-712-3456 | ||
| Grand Blanc | |||
|
|||
| Genesys Regional Medical Center | |||
| Philip J. Stella | Ph: 734-712-3456 | ||
| Grand Rapids | |||
|
|||
| Butterworth Hospital at Spectrum Health | |||
| Gilbert D Padula | Ph: 616-685-5225 | ||
| CCOP - Grand Rapids | |||
| Gilbert D Padula | Ph: 616-685-5225 | ||
| Lacks Cancer Center at Saint Mary's Health Care | |||
| Gilbert D Padula | Ph: 616-685-5225 | ||
| Iron Mountain | |||
|
|||
| Green Bay Oncology - Iron Mountain | |||
| Gerald K. Bayer | Ph: 800-432-6049 | ||
| Jackson | |||
|
|||
| Gayle M. Jacob Cancer Center at Allegiance Health | |||
| Philip J. Stella | Ph: 734-712-3456 | ||
| Kalamazoo | |||
|
|||
| Borgess Medical Center | |||
| Raymond Sterling Lord | Ph: 269-373-7458 | ||
| Bronson Methodist Hospital | |||
| Raymond Sterling Lord | Ph: 269-373-7458 | ||
| West Michigan Cancer Center | |||
| Raymond Sterling Lord | Ph: 269-373-7458 | ||
| Lansing | |||
|
|||
| Sparrow Regional Cancer Center | |||
| Philip J. Stella | Ph: 734-712-3456 | ||
| Livonia | |||
|
|||
| St. Mary Mercy Hospital | |||
| Philip J. Stella | Ph: 734-712-3456 | ||
| Muskegon | |||
|
|||
| Mercy General Health Partners | |||
| Gilbert D Padula | Ph: 616-685-5225 | ||
| Pontiac | |||
|
|||
| St. Joseph Mercy Oakland | |||
| Philip J. Stella | Ph: 734-712-3456 | ||
| Port Huron | |||
|
|||
| Mercy Regional Cancer Center at Mercy Hospital | |||
| Philip J. Stella | Ph: 734-712-3456 | ||
| Reed City | |||
|
|||
| Spectrum Health Reed City Hospital | |||
| Gilbert D Padula | Ph: 616-685-5225 | ||
| Saginaw | |||
|
|||
| Seton Cancer Institute at Saint Mary's - Saginaw | |||
| Philip J. Stella | Ph: 734-712-3456 | ||
| Traverse City | |||
|
|||
| Munson Medical Center | |||
| Gilbert D Padula | Ph: 616-685-5225 | ||
| Warren | |||
|
|||
| St. John Macomb Hospital | |||
| Philip J. Stella | Ph: 734-712-3456 | ||
| Minnesota | |||
|
|||
| Bemidji | |||
|
|||
| MeritCare Bemidji | |||
| Preston D. Steen | Ph: 701-234-6161 | ||
| Burnsville | |||
|
|||
| Fairview Ridges Hospital | |||
| Joseph W Leach | Ph: 952-993-1517 | ||
| Email: MMCCOP@parknicollet.com | |||
| Coon Rapids | |||
|
|||
| Mercy and Unity Cancer Center at Mercy Hospital | |||
| Joseph W Leach | Ph: 952-993-1517 | ||
| Email: MMCCOP@parknicollet.com | |||
| Duluth | |||
|
|||
| CCOP - Duluth | |||
| Daniel Nikcevich | Ph: 888-203-7267 | ||
| Essentia Health - Duluth Clinic | |||
| Daniel Nikcevich | Ph: 888-203-7267 | ||
| Miller - Dwan Medical Center | |||
| Daniel Nikcevich | Ph: 888-203-7267 | ||
| Edina | |||
|
|||
| Fairview Southdale Hospital | |||
| Joseph W Leach | Ph: 952-993-1517 | ||
| Email: MMCCOP@parknicollet.com | |||
| Fridley | |||
|
|||
| Mercy and Unity Cancer Center at Unity Hospital | |||
| Joseph W Leach | Ph: 952-993-1517 | ||
| Email: MMCCOP@parknicollet.com | |||
| Hutchinson | |||
|
|||
| Hutchinson Area Health Care | |||
| Joseph W Leach | Ph: 952-993-1517 | ||
| Email: MMCCOP@parknicollet.com | |||
| Maplewood | |||
|
|||
| HealthEast Cancer Care at St. John's Hospital | |||
| Joseph W Leach | Ph: 952-993-1517 | ||
| Email: MMCCOP@parknicollet.com | |||
| Minnesota Oncology - Maplewood | |||
| Joseph W Leach | Ph: 952-993-1517 | ||
| Email: MMCCOP@parknicollet.com | |||
| Minneapolis | |||
|
|||
| Hennepin County Medical Center - Minneapolis | |||
| Joseph W Leach | Ph: 952-993-1517 | ||
| Email: MMCCOP@parknicollet.com | |||
| Virginia Piper Cancer Institute at Abbott - Northwestern Hospital | |||
| Joseph W Leach | Ph: 952-993-1517 | ||
| Email: MMCCOP@parknicollet.com | |||
| New Ulm | |||
|
|||
| New Ulm Medical Center | |||
| Joseph W Leach | Ph: 952-993-1517 | ||
| Email: MMCCOP@parknicollet.com | |||
| Robbinsdale | |||
|
|||
| Humphrey Cancer Center at North Memorial Outpatient Center | |||
| Joseph W Leach | Ph: 952-993-1517 | ||
| Email: MMCCOP@parknicollet.com | |||
| Rochester | |||
|
|||
| Mayo Clinic Cancer Center | |||
| David James Inwards | Ph: 507-538-7623 | ||
| Saint Louis Park | |||
|
|||
| CCOP - Metro-Minnesota | |||
| Joseph W Leach | Ph: 952-993-1517 | ||
| Email: MMCCOP@parknicollet.com | |||
| Park Nicollet Cancer Center | |||
| Joseph W Leach | Ph: 952-993-1517 | ||
| Email: MMCCOP@parknicollet.com | |||
| Saint Paul | |||
|
|||
| Regions Hospital Cancer Care Center | |||
| Joseph W Leach | Ph: 952-993-1517 | ||
| Email: MMCCOP@parknicollet.com | |||
| United Hospital | |||
| Joseph W Leach | Ph: 952-993-1517 | ||
| Email: MMCCOP@parknicollet.com | |||
| Shakopee | |||
|
|||
| St. Francis Cancer Center at St. Francis Medical Center | |||
| Joseph W Leach | Ph: 952-993-1517 | ||
| Email: MMCCOP@parknicollet.com | |||
| Stillwater | |||
|
|||
| Lakeview Hospital | |||
| Joseph W Leach | Ph: 952-993-1517 | ||
| Email: MMCCOP@parknicollet.com | |||
| Waconia | |||
|
|||
| Ridgeview Medical Center | |||
| Joseph W Leach | Ph: 952-993-1517 | ||
| Email: MMCCOP@parknicollet.com | |||
| Willmar | |||
|
|||
| Willmar Cancer Center at Rice Memorial Hospital | |||
| Joseph W Leach | Ph: 952-993-1517 | ||
| Email: MMCCOP@parknicollet.com | |||
| Woodbury | |||
|
|||
| Minnesota Oncology - Woodbury | |||
| Joseph W Leach | Ph: 952-993-1517 | ||
| Email: MMCCOP@parknicollet.com | |||
| Missouri | |||
|
|||
| Cape Girardeau | |||
|
|||
| Saint Francis Medical Center | |||
| Bethany G. Sleckman | Ph: 913-948-5588 | ||
| Southeast Cancer Center | |||
| Alan Philip Lyss | Ph: 800-392-0936 | ||
| Chesterfield | |||
|
|||
| Saint Luke's Hospital | |||
| Donald F. Busiek | Ph: 314-205-6936 | ||
| Columbia | |||
|
|||
| Ellis Fischel Cancer Center at University of Missouri - Columbia | |||
| Carl E. Freter | Ph: 573-882-7440 | ||
| Jefferson City | |||
|
|||
| Goldschmidt Cancer Center | |||
| Alan Philip Lyss | Ph: 800-392-0936 | ||
| Rolla | |||
|
|||
| Mercy Clinic Cancer and Hematology - Rolla | |||
| Robert L Carolla | Ph: 417-269-4520 | ||
| Phelps County Regional Medical Center | |||
| Robert L Carolla | Ph: 417-269-4520 | ||
| Saint Louis | |||
|
|||
| CCOP - St. Louis-Cape Girardeau | |||
| Bethany G. Sleckman | Ph: 913-948-5588 | ||
| David C. Pratt Cancer Center at St. John's Mercy | |||
| Bethany G. Sleckman | Ph: 913-948-5588 | ||
| Mercy Clinic St. Louis Cancer and Breast Institute | |||
| Bethany G. Sleckman | Ph: 913-948-5588 | ||
| Missouri Baptist Cancer Center | |||
| Alan Philip Lyss | Ph: 800-392-0936 | ||
| Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis | |||
| Nancy L. Bartlett | Ph: 800-600-3606 | ||
| Email: info@siteman.wustl.edu | |||
| Springfield | |||
|
|||
| Cancer Research for the Ozarks | |||
| Robert L Carolla | Ph: 417-269-4520 | ||
| Hulston Cancer Center at Cox Medical Center South | |||
| Robert L Carolla | Ph: 417-269-4520 | ||
| St. John's Regional Health Center | |||
| Robert L Carolla | Ph: 417-269-4520 | ||
| Montana | |||
|
|||
| Billings | |||
|
|||
| Billings Clinic Cancer Center - 801 N 29th Street | |||
| Benjamin Thomas Marchello | Ph: 800-648-6274 | ||
| CCOP - Montana Cancer Consortium | |||
| Benjamin Thomas Marchello | Ph: 800-648-6274 | ||
| Hematology-Oncology Centers of the Northern Rockies - Billings | |||
| Benjamin Thomas Marchello | Ph: 800-648-6274 | ||
| St. Vincent Healthcare Cancer Care Services | |||
| Benjamin Thomas Marchello | Ph: 800-648-6274 | ||
| Bozeman | |||
|
|||
| Bozeman Deaconess Cancer Center | |||
| Benjamin Thomas Marchello | Ph: 800-648-6274 | ||
| Benjamin Thomas Marchello | Ph: 800-648-6274 | ||
| Butte | |||
|
|||
| St. James Healthcare Cancer Care | |||
| Benjamin Thomas Marchello | Ph: 800-648-6274 | ||
| Great Falls | |||
|
|||
| Benefis Sletten Cancer Institute | |||
| Benjamin Thomas Marchello | Ph: 800-648-6274 | ||
| Great Falls Clinic - Main Facility | |||
| Benjamin Thomas Marchello | Ph: 800-648-6274 | ||
| Helena | |||
|
|||
| St. Peter's Hospital | |||
| Benjamin Thomas Marchello | Ph: 800-648-6274 | ||
| Kalispell | |||
|
|||
| Kalispell Regional Medical Center | |||
| Benjamin Thomas Marchello | Ph: 800-648-6274 | ||
| Missoula | |||
|
|||
| Montana Cancer Center at St. Patrick Hospital and Health Sciences Center | |||
| Benjamin Thomas Marchello | Ph: 800-648-6274 | ||
| Montana Cancer Specialists at Montana Cancer Center | |||
| Benjamin Thomas Marchello | Ph: 800-648-6274 | ||
| New Jersey | |||
|
|||
| Camden | |||
|
|||
| Cancer Institute of New Jersey at Cooper University Hospital - Camden | |||
| Gregory A. Masters | Ph: 302-733-6227 | ||
| East Orange | |||
|
|||
| Veterans Affairs Medical Center - East Orange | |||
| Basil S. Kasimis | Ph: 800-475-2336 | ||
| Email: patricia.goyer@med.va.gov | |||
| New York | |||
|
|||
| Bronx | |||
|
|||
| Jack D. Weiler Hospital at Montefiore Medical Center - East Campus | |||
| Ramakrishna Battini | Ph: 718-904-2730 | ||
| Email: aecc@aecom.yu.edu | |||
| Montefiore Medical Center | |||
| Ramakrishna Battini | Ph: 718-904-2730 | ||
| Email: aecc@aecom.yu.edu | |||
| East Syracuse | |||
|
|||
| CCOP - Hematology-Oncology Associates of Central New York | |||
| Jeffrey J. Kirshner | Ph: 315-472-7504 | ||
| Glens Falls | |||
|
|||
| Charles R. Wood Cancer Center at Glens Falls Hospital | |||
| John P Stoutenburg | Ph: 518-926-6700 | ||
| Middletown | |||
|
|||
| Tucker Center for Cancer Care at Orange Regional Medical Center | |||
| Jeffrey M. Stewart | Ph: 845-342-7609 | ||
| New York | |||
|
|||
| New York Weill Cornell Cancer Center at Cornell University | |||
| Peter Martin | Ph: 212-746-1848 | ||
| Rochester | |||
|
|||
| James P. Wilmot Cancer Center at University of Rochester Medical Center | |||
| Jonathan W Friedberg | Ph: 585-275-5830 | ||
| North Carolina | |||
|
|||
| Goldsboro | |||
|
|||
| Wayne Memorial Hospital, Incorporated | |||
| James N. Atkins | Ph: 919-580-0000 | ||
| Hendersonville | |||
|
|||
| Comprehensive Cancer Center at Pardee Hospital | |||
| James E. Radford | Ph: 828-696-4716 | ||
| Kinston | |||
|
|||
| Kinston Medical Specialists | |||
| Peter R. Watson | Ph: 252-559-2200 | ||
| Statesville | |||
|
|||
| Iredell Memorial Hospital | |||
| Ruby A. Grimm | Ph: 704-873-5661 | ||
| North Dakota | |||
|
|||
| Fargo | |||
|
|||
| Roger Maris Cancer Center at MeritCare Hospital | |||
| Preston D. Steen | Ph: 701-234-6161 | ||
| Preston D. Steen | Ph: 701-234-6161 | ||
| Sanford Clinic North-Fargo | |||
| Preston D. Steen | Ph: 701-234-6161 | ||
| Ohio | |||
|
|||
| Akron | |||
|
|||
| Summa Center for Cancer Care at Akron City Hospital | |||
| Jennifer E Payne | Ph: 330-375-6101 | ||
| Barberton | |||
|
|||
| Barberton Citizens Hospital | |||
| Jennifer E Payne | Ph: 330-375-6101 | ||
| Beachwood | |||
|
|||
| Cleveland Clinic Taussig Cancer Center | |||
| Anjali S Advani | Ph: 866-223-8100 | ||
| Cleveland | |||
|
|||
| Case Comprehensive Cancer Center | |||
| Anjali S Advani | Ph: 866-223-8100 | ||
| Cleveland Clinic Cancer Center at Fairview Hospital | |||
| Anjali S Advani | Ph: 866-223-8100 | ||
| Cleveland Clinic Taussig Cancer Center | |||
| Anjali S Advani | Ph: 866-223-8100 | ||
| MetroHealth Cancer Care Center at MetroHealth Medical Center | |||
| Bruce J. Averbook | Ph: 216-778-8526 | ||
| Email: kbauchens@metrohealth.org | |||
| Columbus | |||
|
|||
| Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center | |||
| Kristie A. Blum | Ph: 866-627-7616 | ||
| Email: osu@emergingmed.com | |||
| Dayton | |||
|
|||
| CCOP - Dayton | |||
| Howard M. Gross | Ph: 317-783-8918 | ||
| David L. Rike Cancer Center at Miami Valley Hospital | |||
| Howard M. Gross | Ph: 317-783-8918 | ||
| Good Samaritan Hospital | |||
| Howard M. Gross | Ph: 317-783-8918 | ||
| Grandview Hospital | |||
| Howard M. Gross | Ph: 317-783-8918 | ||
| Samaritan North Cancer Care Center | |||
| Howard M. Gross | Ph: 317-783-8918 | ||
| Findlay | |||
|
|||
| Blanchard Valley Regional Cancer Center | |||
| Howard M. Gross | Ph: 317-783-8918 | ||
| Franklin | |||
|
|||
| Atrium Medical Center | |||
| Howard M. Gross | Ph: 317-783-8918 | ||
| Greenville | |||
|
|||
| Wayne Hospital | |||
| Howard M. Gross | Ph: 317-783-8918 | ||
| Independence | |||
|
|||
| Cleveland Clinic Taussig Cancer Center | |||
| Anjali S Advani | Ph: 866-223-8100 | ||
| Kettering | |||
|
|||
| Charles F. Kettering Memorial Hospital | |||
| Howard M. Gross | Ph: 317-783-8918 | ||
| Mayfield Heights | |||
|
|||
| Hillcrest Cancer Center at Hillcrest Hospital | |||
| Anjali S Advani | Ph: 866-223-8100 | ||
| Parma | |||
|
|||
| Parma Community General Hospital | |||
| Anjali S Advani | Ph: 866-223-8100 | ||
| Sandusky | |||
|
|||
| North Coast Cancer Care, Incorporated | |||
| Anjali S Advani | Ph: 866-223-8100 | ||
| Strongsville | |||
|
|||
| Cleveland Clinic Foundation - Strongsville | |||
| Anjali S Advani | Ph: 866-223-8100 | ||
| Troy | |||
|
|||
| UVMC Cancer Care Center at Upper Valley Medical Center | |||
| Howard M. Gross | Ph: 317-783-8918 | ||
| Wooster | |||
|
|||
| Cleveland Clinic - Wooster | |||
| Anjali S Advani | Ph: 866-223-8100 | ||
| Xenia | |||
|
|||
| Ruth G. McMillan Cancer Center at Greene Memorial Hospital | |||
| Howard M. Gross | Ph: 317-783-8918 | ||
| Oregon | |||
|
|||
| Clackamas | |||
|
|||
| Clackamas Radiation Oncology Center | |||
| Alison K Conlin | Ph: 503-215-6412 | ||
| Milwaukie | |||
|
|||
| Providence Milwaukie Hospital | |||
| Alison K Conlin | Ph: 503-215-6412 | ||
| Newberg | |||
|
|||
| Providence Newberg Medical Center | |||
| Alison K Conlin | Ph: 503-215-6412 | ||
| Oregon City | |||
|
|||
| Willamette Falls Hospital | |||
| Alison K Conlin | Ph: 503-215-6412 | ||
| Portland | |||
|
|||
| CCOP - Columbia River Oncology Program | |||
| Alison K Conlin | Ph: 503-215-6412 | ||
| Providence Cancer Center at Providence Portland Medical Center | |||
| Alison K Conlin | Ph: 503-215-6412 | ||
| Providence St. Vincent Medical Center | |||
| Alison K Conlin | Ph: 503-215-6412 | ||
| Pennsylvania | |||
|
|||
| Philadelphia | |||
|
|||
| Fox Chase Cancer Center - Philadelphia | |||
| Michael M Millenson | Ph: 215-728-4790 | ||
| Pottstown | |||
|
|||
| Pottstown Memorial Regional Cancer Center | |||
| Wei Song | Ph: 610-327-7544 | ||
| Tennessee | |||
|
|||
| Bristol | |||
|
|||
| Blue Ridge Medical Specialists, PC | |||
| Asheesh Shipstone | Ph: 423-578-8538 | ||
| Wellmont-Bristol Regional Medical Center | |||
| Asheesh Shipstone | Ph: 423-578-8538 | ||
| Kingsport | |||
|
|||
| Christine LaGuardia Phillips Cancer Center at Wellmont Holston Valley Medical Center | |||
| Asheesh Shipstone | Ph: 423-578-8538 | ||
| Virginia | |||
|
|||
| Charlottesville | |||
|
|||
| University of Virginia Cancer Center | |||
| Michael Eugene Williams | Ph: 434-243-6143 | ||
| Martinsville | |||
|
|||
| Ravenel Oncology Center at Memorial Hospital of Martinsville and Henry County | |||
| Sreedhar Katragadda | Ph: 276-666-7827 | ||
| Norton | |||
|
|||
| Southwest Virginia Regional Cancer Center at Wellmonth Health | |||
| Asheesh Shipstone | Ph: 423-578-8538 | ||
| Washington | |||
|
|||
| Vancouver | |||
|
|||
| Northwest Cancer Specialists at Vancouver Cancer Center | |||
| Alison K Conlin | Ph: 503-215-6412 | ||
| Southwest Washington Medical Center Cancer Center | |||
| Alison K Conlin | Ph: 503-215-6412 | ||
| West Virginia | |||
|
|||
| Morgantown | |||
|
|||
| Mary Babb Randolph Cancer Center at West Virginia University Hospitals | |||
| Sayed M Hamadani | Ph: 304-293-2745 | ||
| Email: sfilburn@hsc.wvu.edu | |||
| Wisconsin | |||
|
|||
| Antigo | |||
|
|||
| Langlade Memorial Hospital | |||
| Hamied R. Rezazadeh | Ph: 877-405-6866 | ||
| Eau Claire | |||
|
|||
| Center for Cancer Treatment & Prevention at Sacred Heart Hospital | |||
| Ali W. Bseiso | Ph: 715-389-4457 | ||
| Marshfield Clinic Cancer Care at Regional Cancer Center | |||
| Ali W. Bseiso | Ph: 715-389-4457 | ||
| Green Bay | |||
|
|||
| Green Bay Oncology, Limited at St. Mary's Hospital | |||
| Gerald K. Bayer | Ph: 800-432-6049 | ||
| Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center | |||
| Gerald K. Bayer | Ph: 800-432-6049 | ||
| St. Mary's Hospital Medical Center - Green Bay | |||
| Gerald K. Bayer | Ph: 800-432-6049 | ||
| St. Vincent Hospital Regional Cancer Center | |||
| Gerald K. Bayer | Ph: 800-432-6049 | ||
| La Crosse | |||
|
|||
| Gundersen Lutheran Center for Cancer and Blood | |||
| Kurt Oettel | Ph: 608-775-2385 | ||
| Email: cancerctr@gundluth.org | |||
| Madison | |||
|
|||
| University of Wisconsin Paul P. Carbone Comprehensive Cancer Center | |||
| Brad S. Kahl | Ph: 877-405-6866 | ||
| Manitowoc | |||
|
|||
| Holy Family Memorial Medical Center Cancer Care Center | |||
| Gerald K. Bayer | Ph: 800-432-6049 | ||
| Marinette | |||
|
|||
| Bay Area Cancer Care Center at Bay Area Medical Center | |||
| Gerald K. Bayer | Ph: 800-432-6049 | ||
| Marshfield | |||
|
|||
| Marshfield Clinic - Marshfield Center | |||
| Ali W. Bseiso | Ph: 715-389-4457 | ||
| Saint Joseph's Hospital | |||
| Ali W. Bseiso | Ph: 715-389-4457 | ||
| Milwaukee | |||
|
|||
| Froedtert Hospital and Medical College of Wisconsin | |||
| Timothy S Fenske | Ph: 414-805-4380 | ||
| Minocqua | |||
|
|||
| Marshfield Clinic - Lakeland Center | |||
| Ali W. Bseiso | Ph: 715-389-4457 | ||
| Mukwonago | |||
|
|||
| D.N. Greenwald Center | |||
| Michael A Thompson | Ph: 262-928-7632 | ||
| New Richmond | |||
|
|||
| Cancer Center of Western Wisconsin | |||
| Joseph W Leach | Ph: 952-993-1517 | ||
| Email: MMCCOP@parknicollet.com | |||
| Oconomowoc | |||
|
|||
| Regional Cancer Center at Oconomowoc Memorial Hospital | |||
| Michael A Thompson | Ph: 262-928-7632 | ||
| Oconto Falls | |||
|
|||
| Green Bay Oncology, Limited - Oconto Falls | |||
| Gerald K. Bayer | Ph: 800-432-6049 | ||
| Rhinelander | |||
|
|||
| Ministry Medical Group at Saint Mary's Hospital | |||
| Ali W. Bseiso | Ph: 715-389-4457 | ||
| Ali W. Bseiso | Ph: 715-389-4457 | ||
| Rice Lake | |||
|
|||
| Marshfield Clinic - Indianhead Center | |||
| Ali W. Bseiso | Ph: 715-389-4457 | ||
| Sheboygan | |||
|
|||
| Saint Nicholas Hospital | |||
| Gerald K. Bayer | Ph: 800-432-6049 | ||
| Stevens Point | |||
|
|||
| Marshfield Clinic at Saint Michael's Hospital | |||
| Ali W. Bseiso | Ph: 715-389-4457 | ||
| Saint Michael's Hospital Cancer Center | |||
| Ali W. Bseiso | Ph: 715-389-4457 | ||
| Sturgeon Bay | |||
|
|||
| Green Bay Oncology, Limited - Sturgeon Bay | |||
| Gerald K. Bayer | Ph: 800-432-6049 | ||
| Waukesha | |||
|
|||
| Waukesha Memorial Hospital Regional Cancer Center | |||
| Michael A Thompson | Ph: 262-928-7632 | ||
| Wausau | |||
|
|||
| Marshfield Clinic - Wausau Center | |||
| Ali W. Bseiso | Ph: 715-389-4457 | ||
| University of Wisconcin Cancer Center at Aspirus Wausau Hospital | |||
| Hamied R. Rezazadeh | Ph: 877-405-6866 | ||
| Weston | |||
|
|||
| Diagnostic and Treatment Center | |||
| Ali W. Bseiso | Ph: 715-389-4457 | ||
| Marshfield Clinic - Weston Center | |||
| Ali W. Bseiso | Ph: 715-389-4457 | ||
| Ministry Saint Clare's Hospital | |||
| Ali W. Bseiso | Ph: 715-389-4457 | ||
| Wisconsin Rapids | |||
|
|||
| Marshfield Clinic - Wisconsin Rapids Center | |||
| Ali W. Bseiso | Ph: 715-389-4457 | ||
| Wyoming | |||
|
|||
| Casper | |||
|
|||
| Rocky Mountain Oncology | |||
| Benjamin Thomas Marchello | Ph: 800-648-6274 | ||
| Sheridan | |||
|
|||
| Welch Cancer Center at Sheridan Memorial Hospital | |||
| Benjamin Thomas Marchello | Ph: 800-648-6274 | ||
Link to the current ClinicalTrials.gov record.
NLM Identifer NCT01415752
Information obtained from ClinicalTrials.gov on December 09, 2012
Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain
the same text. Minor
changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and
contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should
be directed to ClinicalTrials.gov.
Back to Top
